EUVIMEDEUVIMED entdecken
Multizentrische Studie

Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype

Rana Ajabnoor, Gloria Zhang, Yan Hu, Yuan Gao, Brian S Finkelman, Bradley M Turner, Sha Yi, Ajay Dhakal, William Audeh, Zaibo Li, Xiaoxian Li, David G Hicks und 1 weitere

Modern Pathology · 2024

DOI: 10.1016/j.modpat.2024.100530 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Modern Pathology, 2024. Verfasst von Rana Ajabnoor und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Rochester Medical Center, Rochester, New York; Department of Pathology, Faculty of Medicine, King Abdulaziz Un…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Immunohistochemistry, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: AstraZeneca, Agendia, Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) with average human epidermal growth factor receptor 2 (HER2) signals/cell ≥6 and HER2/chromosome enumeration probe 17 (CEP17) ratio

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesImmunohistochemistryBiomarkers, TumorHumansFemaleMiddle AgedAdultAgedRetrospective StudiesAged, 80 and overIn Situ HybridizationChromosomes, Human, Pair 17

Stichwörter der Autor:innen

HER2HER2-targeted therapyISH group 3breast cancercoamplified/polysomymolecular subtype

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Pathology, University of Rochester Medical Center, Rochester, New York; Department of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
  • Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio.
  • Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
  • Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, Georgia.
  • Department of Pathology, University of Rochester Medical Center, Rochester, New York.
  • Department of Medicine, University of Rochester Medical Center, Rochester, New York.

Förderung

  • AstraZeneca
  • Agendia
  • Gilead Sciences

Zitieren

APA

Ajabnoor, R., Zhang, G., Hu, Y., Gao, Y., Finkelman, B. S., Turner, B. M., Yi, S., Dhakal, A., Audeh, W., Li, Z., Li, X., Hicks, D. G., & Zhang, H. (2024). Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype. Modern Pathology. https://doi.org/10.1016/j.modpat.2024.100530

Vancouver

Ajabnoor R, Zhang G, Hu Y, Gao Y, Finkelman BS, Turner BM, et al. Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype. Modern Pathology. 2024. doi:10.1016/j.modpat.2024.100530

BibTeX
@article{Ajabnoor2024,
  author = {Ajabnoor, Rana and Zhang, Gloria and Hu, Yan and Gao, Yuan and Finkelman, Brian S and Turner, Bradley M and Yi, Sha and Dhakal, Ajay and Audeh, William and Li, Zaibo and Li, Xiaoxian and Hicks, David G and Zhang, Huina},
  title = {Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype},
  journal = {Modern Pathology},
  year = {2024},
  doi = {10.1016/j.modpat.2024.100530}
}
Kostenlos starten →